Core E: Cellular and Organismic Systems for Antiviral Testing

用于抗病毒检测的核心E -细胞和器官系统 总结 蜂窝和器官系统核心通过协调和支持整个中西部AViDD中心， 实施细胞和动物抗病毒测试实验，以实现每个项目的目标。 一个细胞和器官系统核心组是必要的，因为需要这个AViDD中心， 在确定每种化合物的抗病毒活性方面的一致性，并且由于对 处理需要高度控制的病原体。总部设在明尼苏达大学、波士顿大学和 爱荷华州大学的细胞和器官系统核心提供了专门的资源， 执行细胞和动物BSL 2、BSL 3、BSL 4研究的行政框架。核心E将专注于 SARS-CoV-2、寨卡病毒、埃博拉病毒和拉沙病毒。该核心将通过高质量的 目标1中的通量筛选。成功的化合物将返回项目和核心， 精致。Aim 2将评估精制化合物的抗病毒活性和剂量反应， 逃逸和在原代人类细胞中的功效。最后，在目标2中证明功效的化合物将在本发明的范围内。 在目的3中的相关动物疾病模型中评价预防和治疗功效。

Core E – Cellular and Organismic Systems for Antiviral Testing Summary The Cellular and Organismic Systems Core supports the entire Midwest AViDD Center by coordinating and implementing cell and animal antiviral testing experiments required to address the aims in each of the Projects. A Cellular and Organismic Systems Core group is necessary for this AViDD Center because of the need for consistency in determining the antiviral activity of each compound, and because of the intense requirements for handling pathogens that require high containment. Based at the University of Minnesota, Boston University and the University of Iowa, the Cellular and Organismic Systems Core provides the specialized resources and administrative framework for performing cellular and animal BSL2, BSL3, BSL4 studies. Core E will focus on SARS-CoV-2, Zika virus, Ebola virus and Lassa virus. This core will evaluate validated hits through high throughput screening in Aim 1. Successful compounds will then go back to the projects and cores for further refinement. Aim 2 will then evaluate refined compounds for antiviral activity and dose response, the potential for escape, and efficacy in primary human cells. Finally, compounds that demonstrate efficacy in Aim 2 will be evaluated for prophylactic and therapeutic efficacy in relevant animal disease models in Aim 3.